





F


Supplementary Figure 1. T47D (A) and BT474 (C) cells were pretreated with a PI3K inhibitor (BEZ235, $1 \mu \mathrm{M}$ ), a MEK1/2 inhibitor (AZD6244, $5 \mu \mathrm{M}$ ), a MEK5 inhibitor (BIX02189, $10 \mu \mathrm{M}$ ) and with double and triple combinations of these inhibitors for 2 hours. Later, they were then stimulated with NRG for 24 hours. The expression levels of ER $\alpha$, PR and several of the downstream proteins involved in NRG receptor signaling were performed by Western blot. ( $B$ and $D$ ) The graphics represent the quantitation of ER $\alpha$ levels corresponding to the mean $\pm$ SD of data from two independent experiments as performed in A and C. (E) MCF7 cells were pretreated with a PI3K $\alpha$ inhibitor (Alpelisib, $1 \mu \mathrm{M}$ ) plus an mTOR inhibitor (Rapamycin, 100 nM ), a MEK1/2 inhibitor (Trametinib, 100 nM ) and an ERK5 inhibitor (JWG071, $5 \mu \mathrm{M}$ ) for 2 hours. Later, they were then stimulated with NRG for 24 hours. The expression levels of ER $\alpha$, PR and several of the downstream proteins involved in NRG receptor signaling were performed by Western blot. (F) The graphics represents the quantitation of $E R \alpha$ levels corresponding to the experiment performed in $E$.


Supplementary Figure 2. (A) Dose-response analyses of the effect of fulvestrant on BT474 and T47D cells. Cells were treated with fulvestrant at the indicated doses and cell proliferation was determined by MTT metabolization 4 days later. The data are plotted as the percentage of MTT metabolization with respect to control. Results are shown as the mean $\pm$ SD of quadruplicates of an experiment repeated three times. (B) Levels of expression of ER $\alpha$ in MCF7 cells treated with NRG (10 nM) plus fulvestrant $(1 \mu \mathrm{M})$ for 48 hours. The graphic represents the quantitation of the ER $\alpha$ levels corresponding to the upper panel. (C) Effect of the expression of NRG in MCF7Tetoff-NRG $\alpha 2 \mathrm{c}$ cells treated with fulvestrant. MCF7 ${ }^{\text {Tetoff- }}$ NRG $\alpha 2 \mathrm{c}$ cells were treated with doxycycline ( 10 nM ) for 72 hours, and later the cells were treated with the indicated doses of fulvestrant. Cell proliferation was determined by MTT metabolization 4 days later. The data are plotted as the percentage of MTT metabolization with respect to control. Results are shown as the mean $\pm$ SD of duplicates of an experiment repeated two times. The expression of proNRG $\alpha 2 \mathrm{c}$ in MCF7 Tetoff-NRG $\alpha 2 \mathrm{c}$ cells treated with doxycycline was analyzed by Western blot.

Supplementary Figure 2


Supplementary Figure 3. (A-B) Effect of NRG in MCF7 or BT474 cells treated with fulvestrant. MCF7 (A) or BT474 (B) cells were stimulated with NRG ( 10 nM ) for 24 hours, and later the cells were treated with fulvestrant $(1 \mu \mathrm{M})$. Cell proliferation was determined by cell counting 4 days later. The data are plotted as the percentage of the number of cells respect to control. Results are shown as the mean $\pm$ SD of triplicates of an experiment repeated two times. (C-D) Effect of NRG in MCF7 or BT474 cells treated with fulvestrant. MCF7 (C) or BT474 (D) cells were stimulated and treated like experiments performed in A and B. Moreover, this experiment was also carried out in the reverse way, (pre-treating 24 hours with fulvestrant, and later stimulating with NRG for 4 days). Cell proliferation was determined by MTT metabolization. The data are plotted as the percentage of MTT metabolization with respect to control. Results are shown as the mean $\pm$ SD of quadruplicates of an experiment repeated two times.

## Supplementary figure 3

| A | B |  |  |  |  | C |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | ESR1 | PGR |  | ESR1 | PGR |  | ESR1 | PGR |
|  | MannWhitney U (p-value) | MannWhitney U (p-value) |  | MannWhitney U (p-value) | MannWhitney U (p-value) |  | MannWhitney U (p-value) | MannWhitney U (p-value) |
| C vs. 1h | <0.05 | <0.05 | C vs. 1h | $>0.05$ | $>0.05$ | C vs. 1 h | >0.05 | >0.05 |
| C vs. 3h | <0.05 | <0.05 | C vs. 3h | <0.05 | >0.05 | C vs. 3h | <0.05 | <0.05 |
| C vs. 6 h | <0.05 | <0.05 | C vs. 6 h | <0.05 | <0.05 | C vs. 6 h | $>0.05$ | <0.05 |
| C vs. 12h | <0.05 | <0.05 | C vs. 12h | <0.05 | <0.05 | C vs. 12h | $<0.05$ | <0.05 |
| C vs. 24 h | <0.05 | <0.05 | C vs. 24 h | <0.05 | <0.05 | C vs. 24h | <0.05 | <0.05 |
| C vs. 48h | <0.05 | $>0.05$ | C vs. 48 h | <0.05 | <0.05 | C vs. 48h | <0.05 | <0.05 |
| MCF7 |  |  | T47D |  |  | BT474 |  |  |

Supplementary Table 1

| A | B |  |  |  |  | $\mathbf{C}$ |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | ESR1 | PGR |  | ESR1 | PGR |  | ESR1 | PGR |
|  | MannWhitney U (p-value) | MannWhitney U (p-value) |  | MannWhitney U (p-value) | MannWhitney U (p-value) |  | MannWhitney U (p-value) | MannWhitney U (p-value) |
| C (N) vs. BEZ (N) | <0.05 | >0.05 | C (N) vs. BEZ (N) | <0.05 | >0.05 | C (N) vs. BEZ (N) | <0.05 | >0.05 |
| $\mathrm{C}(\mathrm{N})$ vs. AZD (N) | <0.05 | >0.05 | C (N) vs. AZD (N) | >0.05 | >0.05 | C (N) vs. AZD (N) | >0.05 | >0.05 |
| C (N) vs. BIX (N) | <0.05 | >0.05 | C (N) vs. BIX (N) | >0.05 | $>0.05$ | $C$ (N) vs. BIX (N) | >0.05 | >0.05 |
| $C(N)$ vs. $B+A+B(N)$ | <0.05 | >0.05 | $C(N)$ vs. $B+A+B(N)$ | >0.05 | >0.05 | $C(N)$ vs. $B+A+B(N)$ | <0.05 | <0.05 |
| MCF7 |  |  | T47D |  |  | BT474 |  |  |

Supplementary Table 2

